Stabilization of Plaque Using Darapladib–Thrombolysis in Myocardial Infarction 52 - SOLID-TIMI 52


The goal of the trial was to evaluate treatment with darapladib compared with placebo among participants within 30 days of an acute coronary syndrome (ACS). Darapladib is a direct lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor that reduces Lp-PLA2 activity in plasma and atherosclerotic plaques.